In terms of tumor subtypes determined by HR and HER2, HR+ /HER2− subtypes were observed in 2039 patients (77.8%), HR+ /HER2+ in 154 (5.9%), HR− /HER2+ 176 (6.7%), and HR−/HER2− (triple negative; TN) in 253 (9.6%). This evidence concerns the gene ERBB2 and neoplasm.